TME Pharma announces 33% of patients receiving NOX-A12 in combination with bevacizumab and radiotherapy achieve two year survival in GLORIA phase 1/2 trial in brain cancer
Two of six patients receiving NOX-A12 in combination with bevacizumab and radiotherapy exceeded 24-month survival si…